Literature DB >> 29268328

Under-treatment of small cell lung cancer: the case for surgical resection.

Kathryn E Engelhardt1,2, David D Odell1,3,4, Malcolm M DeCamp3,4.   

Abstract

Entities:  

Year:  2017        PMID: 29268328      PMCID: PMC5723810          DOI: 10.21037/jtd.2017.08.156

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  18 in total

1.  Surgical resection should be considered for stage I and II small cell carcinoma of the lung.

Authors:  Benny Weksler; Katie S Nason; Manisha Shende; Rodney J Landreneau; Arjun Pennathur
Journal:  Ann Thorac Surg       Date:  2012-03-17       Impact factor: 4.330

Review 2.  Surgery for limited-stage small-cell lung cancer.

Authors:  Hayley Barnes; Katharine See; Stephen Barnett; Renée Manser
Journal:  Cochrane Database Syst Rev       Date:  2017-04-21

Review 3.  Potential Pitfalls of Reporting and Bias in Observational Studies With Propensity Score Analysis Assessing a Surgical Procedure: A Methodological Systematic Review.

Authors:  Guillaume Lonjon; Raphael Porcher; Patrick Ergina; Mathilde Fouet; Isabelle Boutron
Journal:  Ann Surg       Date:  2017-05       Impact factor: 12.969

4.  Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up.

Authors:  W Fox; J G Scadding
Journal:  Lancet       Date:  1973-07-14       Impact factor: 79.321

Review 5.  Small cell lung cancer: where do we go from here?

Authors:  Lauren Averett Byers; Charles M Rudin
Journal:  Cancer       Date:  2014-10-21       Impact factor: 6.860

6.  Lobectomy leads to optimal survival in early-stage small cell lung cancer: a retrospective analysis.

Authors:  John M Varlotto; Abram Recht; John C Flickinger; Laura N Medford-Davis; Anne-Marie Dyer; Malcolm M DeCamp
Journal:  J Thorac Cardiovasc Surg       Date:  2011-09       Impact factor: 5.209

7.  Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.

Authors:  Joe Y Chang; Suresh Senan; Marinus A Paul; Reza J Mehran; Alexander V Louie; Peter Balter; Harry J M Groen; Stephen E McRae; Joachim Widder; Lei Feng; Ben E E M van den Borne; Mark F Munsell; Coen Hurkmans; Donald A Berry; Erik van Werkhoven; John J Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J A Haasbeek; Larry S Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J Slotman; Egbert F Smit; Jack A Roth
Journal:  Lancet Oncol       Date:  2015-05-13       Impact factor: 41.316

8.  Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated?

Authors:  David Schreiber; Justin Rineer; Jeremy Weedon; Dan Vongtama; Angela Wortham; Anne Kim; Peter Han; Kwang Choi; Marvin Rotman
Journal:  Cancer       Date:  2010-03-01       Impact factor: 6.860

9.  The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer.

Authors:  Eric Vallières; Frances A Shepherd; John Crowley; Paul Van Houtte; Pieter E Postmus; Desmond Carney; Kari Chansky; Zeba Shaikh; Peter Goldstraw
Journal:  J Thorac Oncol       Date:  2009-09       Impact factor: 15.609

10.  The National Cancer Data Base: a powerful initiative to improve cancer care in the United States.

Authors:  Karl Y Bilimoria; Andrew K Stewart; David P Winchester; Clifford Y Ko
Journal:  Ann Surg Oncol       Date:  2008-01-09       Impact factor: 5.344

View more
  2 in total

1.  Surgery for small cell lung cancer in the modern era: opportunities and challenges.

Authors:  Elliot Wakeam
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

2.  Stage I and II Small-Cell Lung Cancer-New Challenge for Surgery.

Authors:  Fabian Doerr; Sebastian Stange; Maximilian Michel; Georg Schlachtenberger; Hruy Menghesha; Thorsten Wahlers; Khosro Hekmat; Matthias B Heldwein
Journal:  Lung       Date:  2022-06-30       Impact factor: 3.777

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.